Business Context and Reporting Period
Company: CorMedix Inc. (CRMD)
Filing Type: Form 8-K (Current Report)
Date of Report: March 6, 2026
Principal Office: Parsippany, NJ
Event: Regulation FD Disclosure regarding an updated investor presentation and a clarification of financial guidance.
Key Financial Metrics
This filing does not report historical financial results, revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on forward-looking guidance and the correction of a prior statement.
Material Changes and Guidance Clarification
- Guidance Reaffirmation: The Company reaffirmed its full-year 2027 DefenCath sales guidance of $100 million to $140 million, originally provided in a press release dated January 8, 2026.
- Correction of Record: Management clarified that a statement made during the March 5, 2026 earnings call, which cited a range of $100 million to $125 million, was inadvertent and incorrect.
- Updated Materials: An updated investor presentation was released and attached as Exhibit 99.1.
Outlook, Risks, and Management Commentary
The filing contains standard forward-looking statements regarding management's expectations and plans. The Company cautions that actual results may differ materially from projections due to various risks and uncertainties. Investors are directed to the Risk Factors in the most recent Form 10-K for a detailed discussion of these risks. The Company assumes no obligation to update these forward-looking statements except as required by law.
Investor Verification Checklist
- Verify the full-year 2027 DefenCath sales guidance range of $100 million to $140 million against the January 8, 2026 press release.
- Review the updated investor presentation (Exhibit 99.1) for additional strategic details.
- Consult the most recent Form 10-K for comprehensive risk factors affecting the achievement of the stated guidance.
- Note that the March 5, 2026 earnings call reference to a $100 million to $125 million range should be disregarded.